DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering July 27, 2015 • 9:35 AM EDT
DelMar Pharmaceuticals Expands GBM Clinical Trial with Fifth Clinical Trial Site Added in Denver, Colorado July 20, 2015 • 7:35 AM EDT
DelMar Pharmaceuticals to Present Updated Phase I/II Clinical Data on VAL-083 in the Treatment of Refractory Glioblastoma Multiforme at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma July 9, 2015 • 7:35 AM EDT
DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015 June 15, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015 June 10, 2015 • 8:35 AM EDT
Del Mar Pharmaceuticals Inc. (DMPI) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10 June 4, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO June 1, 2015 • 2:29 PM EDT
DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme June 1, 2015 • 8:35 AM EDT
DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme May 29, 2015 • 7:35 AM EDT
DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations May 27, 2015 • 7:05 AM EDT